Page 1 of 1

Approval

Posted: Sun Jan 20, 2019 1:04 am
by Gwikley
Without a major firms marketing, sales force, contacts and it's own reputation, approval of this drug is, in and of itself, not a blanket guarantee that it will have a commercial success. One of the downsides of the loss of the JnJ partnership. Going it alone, through the P3, and beyond ....to the market, will present little GERON with a unique set of challenges. Ones that they have not encountered before. But I'm sure would welcome.

Re: Approval

Posted: Sun Jan 20, 2019 2:02 pm
by Ryan
Having key institutions worldwide already involved in the trials, with their clinicians trained, will help facilitate this uptake.

This is the kind of problem I would be extremely happy with, and most likely quite a while away.*
*Although provisional approval in the Triple Negative cohort should be given immediately from my vantage point. No breath-holding here.